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Introduction Cardiovascular mortality of patients with
combined peripheral arterial disease (PAD) and coronary
artery disease (CAD) is twice as high as that in those with
either disease alone. It is known that patients with PAD
undergoing percutaneous coronary intervention have a
higher incidence of adverse cardiac events such as
myocardial infarction or target vessel revascularization.
Objective In this study, we compared the detailed
characteristics of culprit and nonculprit plaques between
patients with and those without PAD using optical
coherence tomography.
Patients and methods We performed propensity score
matching using the following variables: (i) age; (ii) sex;
(iii) clinical presentation; (iv) diabetes mellitus; (v)
hyperlipidemia; (vi) smoking; (vii) hypertension; (viii) BMI;
and (ix) coronary lesion location. Finally, we matched 34
culprit lesions and 30 nonculprit lesions in patients with
PAD to 68 culprit lesions and 60 nonculprit lesions in
patients without PAD (1 : 2 ratio).
Results In culprit lesions, PAD patients when compared
with those without PAD had a higher prevalence of lipid-rich
plaque (73.5 vs. 51.5%; P= 0.033), higher lipid index
(1744±1110 vs. 1246±656; P= 0.043), calcification
(79.4 vs. 58.8%; P= 0.039), macrophage accumulation
(70.6 vs. 48.5%; P= 0.034), and cholesterol crystals (32.4 vs.
10.3%; P= 0.006). In nonculprit lesions, PAD patients had a
higher prevalence of calcification (76.7 vs. 55.0%; P= 0.046),
macrophage accumulation (63.3 vs. 38.3%; P= 0.025), and
cholesterol crystals (36.7 vs. 16.7%; P= 0.034).
Conclusion Our study suggests greater coronary plaque
vulnerability in both culprit and nonculprit lesions in patients
with PAD. This observation underscores the need for
more aggressive risk management in patients with
combined PAD and coronary artery disease. Coron Artery
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Introduction
The prevalence of peripheral artery disease (PAD)
increases with age, reaching up to 20% in patients older
than 70 years [1]. PAD is associated with both higher
clinical event rates and mortality [2]. Most of these
clinical events are attributed to coronary atherosclerosis –
the cardiovascular risk profile is more pronounced in
concomitant coronary artery disease (CAD) and PAD
[3–5]. In the REACH registry, the 1-year risk for cardi-
ovascular death, myocardial infarction, stroke, or hospi-
talization for atherothrombotic events exceeded 23% in
patients with concomitant PAD and CAD, whereas it
ranged between 13 and 17% for either disease alone.
All-cause mortality of patients with combined lower-
extremity PAD and CAD was twice as high as that in
those with either disease alone [4]. Further, patients with
PAD undergoing percutaneous coronary intervention are
known to have a higher incidence of adverse cardiac
events such as myocardial infarction or target vessel
revascularization [6]. Differences in coronary plaque
phenotype may explain the differences in outcomes.
Therefore, in this study, we compared the detailed
characteristics of both culprit and nonculprit plaques
between patients with and those without PAD using
optical coherence tomography (OCT).
Patients and methods
Study population
Participants were selected from the Massachusetts
General Hospital (MGH) OCT Registry. The MGH
OCT Registry is an ongoing, international, multicenter
registry of patients who have undergone OCT of the
coronary arteries and involves 20 sites across six countries
(NCT01110538). In our study, PAD was defined as
follows: previous aorto-femoral bypass surgery, limb
bypass surgery, or percutaneous transluminal angioplasty
of the iliac or infrainguinal arteries; previous limb or foot
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amputation for arterial vascular disease; carotid artery
stenosis, significant peripheral artery stenosis; or ankle/
arm blood pressure ratio less than 0.80 [7]. We have
identified 88 patients with PAD and performed pro-
pensity score matching between lesions of patients with
and lesions of those without PAD at a 1 : 2 ratio.
As previous studies have reported that (i) age, (ii) sex,
(iii) clinical presentation, (iv) diabetes mellitus, (v)
hyperlipidemia, (vi) smoking, (vii) hypertension, and
(viii) BMI influence plaque burden and plaque char-
acteristics, we have used those variables as matching
criteria [8–11]. In addition, we have matched for coronary
lesion location. As a patient has only one culprit lesion,
patient or lesion can be used interchangeably. However,
with regard to nonculprit lesion, one patient may have
two or more nonculprit lesions in different segments or
even in different vessels. Therefore, nonculprit lesion of
each PAD patient was matched to two lesions in the same
segment of the artery in non-PAD patients. Even though
we matched lesion locations, the lesion phenotype was
not matched. Patients without prepercutaneous coronary
intervention OCT, with poor image quality of OCT, or
with incomplete imaging of the entire lesion were
excluded from the analysis (n= 44). The registry was
approved by the Institutional Review Board at each
participating site. Written informed consent was obtained
from all patients before enrollment.
Image acquisition and analysis
A frequency-domain OCT system (St. Jude Medical, St.
Paul, Minnesota, USA) and a time-domain OCT system
(LightLab Imaging Inc., Westford, Massachusetts, USA)
were used to acquire images. The technique of intra-
coronary OCT imaging has been previously described
[12]. All images were de-identified, digitally stored, and
submitted to the Massachusetts General Hospital
(Boston, Massachusetts, USA). All OCT images were
analyzed at every 1-mm interval.
Lipid-rich plaque (LRP) was defined as a plaque with
maximum lipid arc greater than 90°. Lipid index was
calculated as mean lipid arc multiplied by lipid length
[13]. In addition, the presence or absence of thin-cap
fibroatheroma (TCFA), macrophage accumulation, cho-
lesterol crystal, and microvessel was noted. TCFA was
defined as a LRP with fibrous cap thickness less than or
equal to 65 µm [14]. Macrophage accumulation on the
OCT images was identified by increased granular signal
intensity within the plaque accompanied by hetero-
genous back shadows [15,16]. Cholesterol crystals were
characterized as high-intensity thin linear region adjacent
to a lipid core. Microvessel was defined as small vesicular
or tubular structures with diameter 50–300 µm.
Calcification was also recorded in areas with low back-
scatter and sharp borders inside a plaque [17].
Statistical analysis
Categorical data are presented as counts and %. The
normality of distributions of continuous variables was
examined using the Kolgormonov–Smirnov test. The
mean and SD are reported for normally distributed data,
and the median (25th–75th percentiles) is reported for
data that were not normally distributed. Fisher’s exact
test or the χ2-test was used to analyze categorical vari-
ables and Student’s t-test or Mann–Whitney’s U-test for
continuous variables. Statistical significance was defined
as P less than 0.05. All statistical analyses were performed
with SPSS 23.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Culprit lesions
We matched 34 culprit lesions of 34 PAD patients to 68
lesions of 68 patients without PAD. The average age was
65 years and 74 (72.5%) patients were male (Table 1).
β-Blockers were less frequently used in PAD patients
and approximately one-third of the patients presented
with stable angina.
With regard to culprit plaques, PAD patients had a higher
prevalence of LRP with greater lipid burden, calcifica-
tion, macrophage accumulation, and cholesterol crystals
(Fig. 1 and Table 2). There was a trend toward higher
prevalence of TCFA in the PAD group.
Nonculprit lesions
Wematched 30 nonculprit lesions from 21 PAD patients to
60 nonculprit lesions from 56 patients without PAD. In the
subgroup of patients with nonculprit lesions (demographics
in Supplementary Tables, Supplemental digital content 1,
http://links.lww.com/MCA/A157 and Supplemental digital
content 2, http://links.lww.com/MCA/A158) PAD patients had
longer plaques and higher prevalence of calcification,
Table 1 Baseline characteristics
PAD (n=34) Non-PAD (n=68) P
Age (mean ±SD) (years) 65.4 ±10.2 64.6 ± 4.3 0.680
Sex (male) 24 (70.6) 50 (73.5) 0.754
BMI (mean ±SD) (kg/m2) 25.3 ±3.9 26.0 ±4.3 0.405
Diabetes mellitus 16 (47.1) 26 (38.2) 0.393
Hypertension 24 (70.6) 50 (73.5) 0.754
Hyperlipidemia 27 (79.4) 51 (75.0) 0.620
Current smoker 11 (32.4) 20 (29.4) 0.761
Medications
Aspirin 21 (61.8) 40 (58.8) 0.775
Clopidogrel 9 (26.5) 12 (17.6) 0.299
β-Blocker 6 (17.6) 26 (38.2) 0.035
ACEI or ARB 12 (35.3) 25 (36.8) 0.884
Statin 23 (67.6) 34 (50.0) 0.091
Presentation 0.627
Stable angina 11 (32.4) 22 (32.4)
Unstable angina 15 (44.1) 29 (42.6)
AMI 8 (23.5) 17 (25.0)
Values are mean ±SD or n (%).
ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction;
ARB, angiotensin II receptor blocker; PAD, peripheral artery disease.
Bold values statistically significant (P <0.05).
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Fig. 1
Comparison of culprit and nonculprit plaque characteristics between patients with and those without peripheral artery disease. (a) Culprit lesions in
patients with peripheral artery disease (PAD) had significantly higher prevalence of lipid-rich plaque (LRP), calcification, macrophages, and cholesterol
crystals. (b) Although there were no differences in the prevalence of LRP in nonculprit lesions between patients with and those without PAD, we
observed significant differences in the frequency of calcification, macrophages and cholesterol crystals. Thin-cap fibroatheroma (TCFA) was twice as
frequent in both culprit and nonculprit lesions of patients with PAD as compared with that in patients without PAD (a, b).
Table 2 Culprit lesions optical coherence tomography findings
PAD (n=34) Non-PAD (n=68) P
Plaque length (mm) 16.8 ±7.7 16.4 ± 6.6 0.844
Lipid-rich plaque 25 (73.5) 35 (51.5) 0.033
Lipid core length (mm) 10.6 ±5.2 8.9 ± 3.9 0.158
Mean lipid arc (deg.) 171.1 ±35.3 140.5 ± 30.8 0.001
Max lipid arc (deg.) 257.4 ±81.0 206.3 ± 65.1 0.002
Lipid index 1744 ±1110 1246 ± 656 0.043
TCFA 11 (32.4) 11 (16.2) 0.086
FCT (mm) 0.08 ±0.04 0.10 ± 0.04 0.112
Calcification 27 (79.4) 40 (58.8) 0.039
Macrophage accumulation 24 (70.6) 33 (48.5) 0.034
Microvessel 11 (32.4) 17 (25.0) 0.433
Cholesterol crystals 11 (32.4) 7 (10.3) 0.006
Values are mean ±SD or n (%).
FCT, fibrous cap thickness; PAD, peripheral artery disease; TCFA, thin-cap
fibroatheroma.
Bold values statistically significant (P <0.05).
Table 3 Nonculprit lesions optical coherence tomography findings
PAD (n=30) Non-PAD (n=60) P
Plaque length (mm) 15.6 ± 5.5 10.5 ±4.6 < 0.001
Lipid-rich plaque 21 (70.0) 35 (58.3) 0.426
Lipid core length (mm) 8.0 ± 2.8 6.9 ±3.0 0.180
Mean lipid arc (deg.) 139.7 ± 20.2 133.8 ±22.4 0.328
Max lipid arc (deg.) 173.4 ± 32.1 166.7 ±48.1 0.574
Lipid index 1091 ± 393 929 ±475 0.194
TCFA 6 (20.0) 7 (11.7) 0.289
FCT (mm) 0.09 ± 0.03 0.10 ±0.03 0.437
Calcification 23 (76.7) 33 (55.0) 0.046
Macrophage accumulation 19 (63.3) 23 (38.3) 0.025
Microvessels 13 (43.3) 29 (48.3) 0.654
Cholesterol crystals 11 (36.7) 10 (16.7) 0.034
Values are mean ±SD or n (%).
FCT, fibrous cap thickness; PAD, peripheral artery disease; TCFA, thin-cap
fibroatheroma.
Bold values statistically significant (P <0.05).
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macrophage accumulation, and cholesterol crystals (Fig. 1
and Table 3).
Discussion
Patients with PAD are known to have greater plaque
burden, inflammatory burden, and worse endothelial
function, which may explain higher cardiovascular events
[18]. The present study provides insight into the coronary
plaque characteristics of patients with concomitant PAD
and CAD. In our study, we showed that culprit lesions of
PAD patients compared with those in patients without
PAD had greater lipid content as well as more features of
vulnerable plaque, including higher prevalence of macro-
phages. Likewise, nonculprit lesions in PAD patients had
more features of plaque vulnerability.
OCT findings
In an intravascular ultrasound study, Hussein et al. [19]
demonstrated that patients with both CAD and PAD had
greater plaque burden in the coronary trees. However,
intravascular ultrasound with its low axial resolution
(150–200 µm) and poor discrimination of plaque subtypes
cannot assess the detailed plaque morphology. In the
present OCT study, we observed significantly higher
prevalence of macrophages in both culprit and nonculprit
lesions in PAD patients. Macrophages are key inflam-
matory cells that are involved at every phase of athero-
sclerosis, from its genesis to plaque rupture or erosion.
Recent studies found that PAD was associated with
increased levels of local proinflammatory cytokines, some
of which were known to be linked to CAD progression
[20–22]. A previous study showed that the severity of
coronary atherosclerosis was related to the degree of
inflammatory response in the affected PAD limb [23].
This result suggests that not PAD itself, but its systemic
inflammatory activity may be associated with more severe
CAD. In line with this hypothesis and our results, Fleiner
et al. [24] reported that intimal macrophage infiltration of
iliac, carotid, and renal arteries was the greatest in
patients with cardiovascular events in a postmortem
histopathological study. These results are consistent with
our knowledge that atherosclerosis is a panvascular pro-
cess and that inflammation is a key component of
atherogenesis [18,25]. Inflammation is one of the pro-
cesses that lead to the formation of lipid core, which
contributes to lipid burden in the vascular wall, and thus
may explain the greater lipid plaque content and higher
prevalence of TCFA in PAD patients in our study [26].
Although difference in the prevalence of TCFA was not
statistically significant, TCFA was twice as frequent in
patients with PAD compared with that in patients with-
out PAD (32.4 vs. 16.2% in culprit lesions and 20.0 vs.
11.7% in nonculprit lesions). Of note, cardiovascular
magnetic resonance study reported that patients with
more advanced CAD had a higher prevalence of lipid-
rich necrotic core in their carotid arteries [27]. Combined
with our results, these data may imply the coexistence of
a higher prevalence of LRP in both coronary arteries and
peripheral arteries in patients with concomitant PAD and
CAD. Furthermore, several studies reported that patients
with an abnormal ankle-brachial index, greater carotid
artery intima media thickness, or greater carotid artery
stenosis have more complex CAD [28–31]. Moreover, a
recent study observed an association of total peripheral
score, which evaluated the extent of lower-extremity
artery disease, with SYNTAX score [32]. The panvas-
cular inflammatory process observed in our study is
consistent with previous findings.
Our matched analysis showed that patients with PAD
had a higher prevalence of calcification. This result is in
line with previous reports [19]. PAD patients in our study
had greater lipid burden and higher prevalence of mac-
rophage accumulation. In more advanced cases of CAD,
elevated lipid content and inflammatory mediators
induce osteogenic differentiation of vascular smooth
muscle cells in the intima. Moreover, patients with PAD
typically have reduced physical activity. It has been
suggested that sedentary behavior may lead to progres-
sion of calcification in the coronary arteries [18,33].
Cholesterol crystals are more frequently found in arteries
with greater plaque burden and in those with a higher
degree of inflammation [34,35]. This may be a potential
explanation for the observed higher prevalence of
cholesterol crystals in the lesions of PAD patients.
This study may provide an explanation for higher adverse
event rates in patients with concomitant PAD and CAD.
First, large lipid pool, TCFA, and macrophages are the
major components of vulnerable plaque [36]. Recently,
we observed a higher incidence of irregular protrusion
after placing stents on an LRP [37]. In case of plaque
rupture, large lipid cores may translate into more
severe and prolonged thrombotic response [38].
Macrophages, as a component of vulnerable plaque,
secrete matrix metalloproteinase, which destabilizes
plaque and expresses a tissue factor that is a potent
promoter of coagulation [39,40]. Furthermore, increased
prevalence of macrophages has been observed in autopsy
studies of myocardial infarction patients when compared
with that of stable patients [41]. Second, although calci-
fication is not the marker of plaque vulnerability, calci-
fied lesions may influence stent expansion [42,43].
Third, OCT-derived cholesterol crystals may be one of
the features of the vulnerable plaque [44]. Several groups
reported the association between the presence of cho-
lesterol crystals and acute coronary death [41,45,46].
Cholesterol is present in a liquid state in arterial walls.
However, factors such as saturation, temperature, pres-
sure, and pH may individually or in combination trigger
the crystallization of the cholesterol within the vessel wall
[46]. When cholesterol crystalizes from a liquid state to a
solid state, it expands in volume and contributes to
the risk for a cardiovascular event [45]. In addition,
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cholesterol crystals induce inflammation and, in con-
sequence, destabilize atherosclerotic plaque [35].
Our study demonstrated greater panvascular vulnerability
in patients with combined PAD and CAD. Therefore,
this group of patients may have additional benefit from
more aggressive risk management. Magnitude of local
inflammation may be modulated by high-intensity statin
therapy [22,47]. A recent study showed that increased
cytokine levels lead to platelet hyperactivation [48].
Therefore, potent dual-antiplatelet therapy may have an
additional value in this subset of patients.
Limitations
Several limitations of this study should be noted. First,
though data were collected prospectively, the analyses
were performed retrospectively. Second, both frequency-
domain and time-domain OCTs were used. However,
both systems have light sources with the same center
wavelength (1300 nm) and bandwidth, resulting in similar
axial resolution (15 µm). Therefore, it is unlikely that this
difference influenced the results of this study. Third, the
number of patients in our study is relatively small.
Although we observed differences between the two
groups of patients, our observations should be confirmed
by larger studies. Fourth, cholesterol crystals described by
OCT were not histologically validated. Finally, we did
not assess the severity of PAD.
Conclusion
In the present study, compared with patients with only
CAD, patients with concomitant PAD and CAD had
greater plaque vulnerability in the coronary arteries,
suggesting more generalized inflammatory processes in
this group.
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